

**Supplementary Table 1. Pre-transplant patient demographics and tumour characteristics in the overall patient cohort (*n* = 435), patients with cirrhosis and hepatocellular carcinoma undergoing LDLT**

<b>Patient demographics (<i>n</i> = 435)</b>		<b>Values</b>
Age (years)	Median (range)	55 (20-73)
Gender	Male	348 (80%)
	Female	87 (20%)
Primary disease	Hepatitis C	196 (45%)
	Hepatitis B	113 (26%)
	Ethanol	44 (10%)
	NAFLD/NASH	39 (9%)
	Cryptogenic	30 (7%)
	Others	13 (3%)
Non-tumour MELD score	Median (range)	10 (6-38)
Neutrophil lymphocyte ratio (NLR)	Median (IQR)	2.4 (1.7-3.7)
Platelet lymphocyte ration (PLR)	Median (IQR)	435 (292-642)
<b>Tumour characteristics</b>		
Pre-LT AFP ng/mL	Median (IQR), range	24 (7-169), 1-17,500
Number of tumours	Single	221 (55%)
	2-3	117 (29%)
	> 3	65 (16%)
Maximum tumour diameter	Mean $\pm$ SD	4.15 $\pm$ 2.95
Milan Criteria	In/Out	213 (49%)/222 (51%)
UCSF Criteria	In/Out	278 (57%)/187 (43%)
FDG-18 PET (available in 335 patients)	PET avid	168 (50.1%)
	Non PET avid	167 (49.9%)